Navigation Links
Prometic provides information for its Annual and Special Meeting of Shareholders
Date:5/1/2008

MONTREAL, May 1 /PRNewswire-FirstCall/ - ProMetic Life Sciences Inc. ("ProMetic") (TSX:PLI) will host its Annual and Special Meeting of Shareholders on Wednesday, May 7, 2008 at 10:30 a.m. (EDT). The Annual and Special Meeting of Shareholders ("Meeting") will be held at the Montreal Museum of Fine Arts located at 1379 Sherbrooke Street West in Montreal. Points to be covered are:

- Items on the Meeting's agenda as per the Management Information

Circular

- Corporate Presentations

- MacoPharma presents update on launch of P-Capt(R) prion capture

filter

- Protein Technologies business update

- Anemia drugs program update - PBI-1402 and analogues

- Corporate strategy to build shareholder value

Following these presentations shareholders and guests will have the opportunity of viewing displays on ProMetic's various products, as well as meeting members of management and scientists who will be gathered for the occasion.

For those who are unable to attend in person, the Company will offer a live audio webcast through ProMetic's website at http://www.prometic.com. A replay of the webcast will be available following the meeting on ProMetic's website.

About ProMetic Life Sciences Inc.

ProMetic Life Sciences Inc. ("ProMetic") (http://www.prometic.com) is a biopharmaceutical company specialized in the research, development, manufacture and marketing of a variety of commercial applications derived from its proprietary Mimetic Ligand(TM) technology. This technology is used in large-scale purification of biologics and the elimination of pathogens. ProMetic is also active in therapeutic drug development with the mission to bring to market effective, innovative, lower cost, less toxic products for the treatment of hematology and cancer. Its drug discovery platform is focused on replacing complex, expensive proteins with synthetic "drug-like" protein mimetics. Headquartered in Montreal (Canada), ProMetic has R&D facilities in the U.K., the U.S. and Canada, manufacturing facilities in the U.K. and business development activities in the US, Europe, Asia and in the Middle-East.

Forward Looking Statements

This press release contains forward-looking statements about ProMetic's objectives, strategies and businesses that involve risks and uncertainties. These statements are "forward-looking" because they are based on our current expectations about the markets we operate in and on various estimates and assumptions. Actual events or results may differ materially from those anticipated in these forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate. Such risks and assumptions include, but are not limited to, ProMetic's ability to develop, manufacture, and successfully commercialize value-added pharmaceutical products, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of ProMetic to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. You will find a more detailed assessment of the risks that could cause actual events or results to materially differ from our current expectations on page 21 of ProMetic's Annual Information Form for the year ended December 31, 2007, under the heading "Risk Factors". As a result, we cannot guarantee that any forward-looking statement will materialize. We assume no obligation to update any forward-looking statement even if new information becomes available, as a result of future events or for any other reason, unless required by applicable securities laws and regulations.


'/>"/>
SOURCE PROMETIC LIFE SCIENCES INC.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. ProMetic presents preclinical data for prostate and pancreatic cancer at the AACR Meeting
2. ProMetic to obtain controlling stake in Pathogen Removal and Diagnostic Technologies Inc.
3. Prometic to present at the American Chemical Society
4. ProMetic and Sartorius Stedim Biotech collaborate on technology transfer deals in Asia
5. ProMetic reports continued positive data in PBI-1402 phase II trial in chemotherapy-induced anemia
6. ProMetic announces signature of definitive license agreement with Kedrion for two hyperimmune products
7. ProMetic provides business update - Over $35 million worth of business secured in January
8. ProMetic announces scale-up of prion removal resin in plasma product for biopharmaceutical use
9. ProMetic and MacoPharma announce successful completion of P-Capt(R) prion reduction filter clinical studies
10. AEterna Zentaris Partner, Spectrum, Provides Update on Ozarelix in Benign Prostatic Hyperplasia
11. Genzyme Provides Update on Myozyme(R) Manufacturing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... 2017 International research firm Parks Associates announced today ... the TMA 2017 Annual Meeting , October 11 in ... home security market and how smart safety and security products impact the ... Parks Associates: Smart Home Devices: ... "The residential security market has experienced ...
(Date:10/9/2017)... 2017  BioTech Holdings announced today identification and ... ProCell stem cell therapy prevents limb loss in ... demonstrated that treatment with ProCell resulted in more ... compared to standard bone marrow stem cell administration.  ... reduction of therapeutic effect.  ...
(Date:10/9/2017)... San Antonio, Texas (PRWEB) , ... ... ... a new study published on October 5, 2017, in the medical journal, ... demonstrated equivalence with the gold standard, video EEG, in detecting generalized tonic-clonic ...
(Date:10/6/2017)... ... October 06, 2017 , ... The HealthTech Venture ... sector at their fourth annual Conference where founders, investors, innovative practitioners and collaborators ... ELEVATE pitch competition showcasing early stage digital health and med tech companies. , ...
Breaking Biology Technology:
(Date:8/23/2017)... 2017  The general public,s help is being enlisted in what,s thought ... in and on the human body –and are believed to affect health.  ... The Microbiome Immunity Project is the ... with the gut. The project's goal is to help advance scientific knowledge ... ...
(Date:7/20/2017)... , July 20, 2017 Delta (NYSE: DAL ) ... any Delta aircraft at Reagan Washington National Airport (DCA). ... Delta launches biometrics to board ... Delta,s biometric boarding ... Club is now integrated into the boarding process to allow eligible ...
(Date:6/23/2017)... N.Y. , June 23, 2017  IBM (NYSE: ... dairy research, today announced a new collaboration using next-generation ... chances that the global milk supply is impacted by ... Cornell University has become the newest academic institution to ... a food safety initiative that includes IBM Research, Mars, ...
Breaking Biology News(10 mins):